KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $25.6 billion.

  • Vertex Pharmaceuticals' Liabilities and Shareholders Equity rose 1380.1% to $25.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $97.4 billion, marking a year-over-year increase of 968.17%. This contributed to the annual value of $25.6 billion for FY2025, which is 1380.1% up from last year.
  • Vertex Pharmaceuticals' Liabilities and Shareholders Equity amounted to $25.6 billion in Q4 2025, which was up 1380.1% from $24.9 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Liabilities and Shareholders Equity ranged from a high of $25.6 billion in Q4 2025 and a low of $12.1 billion during Q1 2021
  • Moreover, its 5-year median value for Liabilities and Shareholders Equity was $20.2 billion (2023), whereas its average is $19.3 billion.
  • Per our database at Business Quant, Vertex Pharmaceuticals' Liabilities and Shareholders Equity soared by 3622.83% in 2021 and then plummeted by 433.53% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Liabilities and Shareholders Equity stood at $13.4 billion in 2021, then soared by 35.13% to $18.2 billion in 2022, then increased by 25.23% to $22.7 billion in 2023, then decreased by 0.87% to $22.5 billion in 2024, then increased by 13.8% to $25.6 billion in 2025.
  • Its last three reported values are $25.6 billion in Q4 2025, $24.9 billion for Q3 2025, and $24.0 billion during Q2 2025.